Toggle Offcanvas
...
 
Infliximab Tenders

Infliximab Tenders

View Infliximab tenders, RFPs and contracts. Bid on readily available Infliximab tenders with the best and most comprehensive tendering platform, since 2002.

Bidding for Infliximab tenders is extremely lucrative for companies of all sizes. Tendering authorities and private companies release thousands of contracts worth millions for procurement of Infliximab.

Global Tenders stands out as the largest platform dedicated to pharmaceutical tenders and government contracts. Boasting over 20 years of experience in the tender business, GlobalTenders offers the most extensive and reliable Tenders/RFPs/Contracts Database available. The platform aggregates contracts from both public and private sources, connecting with a vast network of over half a million buyers. Employing advanced artificial intelligence, our meticulous process involves gathering information from over a hundred thousand sources. The data is then intelligently categorized into thousands of subcategories for easy filtering and presenting it in a user-friendly format for quick comprehension.

In addition to tender information, we offer in-depth Infliximab market analysis, bid consultancy services, and insights into top bidders and winners.

Sign up now to get instant access to unlimited Infliximab tenders, advanced search filters, market analysis, industry trends, tender training and 24/7 customer support.

29 Live Notices for Infliximab Tenders

Showing 1 to 20

Specific Contract For The Supply Of The Medicinal Specialty Remicade (Infliximab) Through The Dynamic Acquisition System Sda Aria2020305 For The Duration Of 12 Months
country Italy
posting date05 Feb 2025
deadline14 Feb 2025
Framework Agreement For The Supply Of Infliximab
country Belgium
posting date28 Jan 2025
deadline24 Feb 2025
Ct2366/2024 - Tender For The Supply Of Infliximab 100Mg Powder For Concentrate For Solution For Infusion
country Malta
posting date20 Jan 2025
deadline20 Feb 2025
Environmentally Friendly Supply Of Biological Human Medicines With Biosimilars For Public Health Centres In Valencia
country Spain
posting date30 Dec 2024
deadline01 Oct 2025
Conclusion Of Non-Exclusive Discount Agreements According To §130A Para.8 Sgb V For Various Active Ingredients/Combinations With The Possibility Of Conclusion At Any Time Within The Framework Of The So-Called Open House Procedure
country Germany
posting date05 Dec 2024
deadline05 Dec 2026
Conclusion Of Non-Exclusive Discount Agreements According To §130A Para.8 Sgb V For Various Active Ingredients/Combinations With The Possibility Of Conclusion At Any Time Within The Framework Of The So-Called Open House Procedure
country Germany
posting date26 Nov 2024
deadline05 Dec 2026
Conclusion Of A Non-Exclusive Drug Discount Agreement Pursuant To Section 130A Paragraph 8 Of The Social Code Book V By Means Of An Open-House Model For The Active Ingredient Infliximab For Subcutaneous Injection (Atc Code According To Who: L04Ab02)
country Germany
posting date11 Nov 2024
deadline31 Dec 2026
Pharmaceutical Discount Agreements From 01.01.2025 For Various Active Ingredients Within The Framework Of An Open-House Procedure
country Germany
posting date11 Nov 2024
deadline02 Nov 2026
Conclusion Of A Non-Exclusive Drug Discount Agreement Pursuant To Section 130A Paragraph 8 Of The Social Code Book V By Means Of An Open-House Model For The Active Ingredient Infliximab For Subcutaneous Injection (Atc Code According To Who: L04Ab02)
country Germany
posting date11 Nov 2024
deadline31 Dec 2026
Pharmaceutical Discount Agreements From 01.01.2025 For Various Active Ingredients Within The Framework Of An Open-House Procedure
country Germany
posting date11 Nov 2024
deadline02 Nov 2026
Conclusion Of A Non-Exclusive Drug Discount Agreement Pursuant To Section 130A Paragraph 8 Of The Social Code Book V By Means Of An Open-House Model For The Active Ingredient Infliximab For Subcutaneous Injection (Atc Code According To Who: L04Ab02)
country Germany
posting date11 Nov 2024
deadline31 Dec 2026
Pharmaceutical Discount Agreements From 01.01.2025 For Various Active Ingredients Within The Framework Of An Open-House Procedure
country Germany
posting date11 Nov 2024
deadline02 Nov 2026
Open House Drug Rebate Agreements Infliximab, Atc L04Ab02
country Germany
posting date17 Sep 2024
deadline05 Sep 2026
Open House Drug Rebate Agreements Infliximab, Atc L04Ab02
country Germany
posting date17 Sep 2024
deadline05 Sep 2026
Conclusion Not Excluding Drug Discount Agreement. According To Section 130A Paragraph 8 Sgb V Through An Open House Model For The Active Ingredient Infliximab (Atc Code According To Who: L04Ab02)
country Germany
posting date27 Mar 2024
deadline31 May 2025
Conclusion Not Excluding Drug Discount Agreement. According To Section 130A Paragraph 8 Sgb V Through An Open House Model For The Active Ingredient Infliximab (Atc Code According To Who: L04Ab02)
country Germany
posting date27 Mar 2024
deadline31 May 2025
Medicines With The Active Ingredient Infliximab - In The Dosage Form Powder (Atc:L04Ab02)
country Germany
posting date22 Sep 2023
deadline31 Aug 2025
Medicines With The Active Ingredient Infliximab - In The Dosage Form Injection Solution (Atc: L04Ab02)
country Germany
posting date22 Sep 2023
deadline31 Aug 2025
Medicines With The Active Ingredient Infliximab - In The Dosage Form Injection Solution (Atc: L04Ab02)
country Germany
posting date20 Sep 2023
deadline31 Aug 2025
Medicines With The Active Ingredient Infliximab - In The Dosage Form Powder (Atc:L04Ab02)
country Germany
posting date20 Sep 2023
deadline31 Aug 2025

Share Share this page